• Japanese
  • Korean
  • Chinese
Cover Image

Growth Factors (Blood and Tissue)

This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 90 companies including many key and niche players such as -

Alseres Pharmaceuticals, Inc.
Amgen, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biogen Idec Inc.
BioMimetic Therapeutics, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Blood Growth Factors
      • Erythropoietins
      • Colony Stimulating Factors
      • Interferons
      • Interleukins
    • Tissue Growth Factors

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Growth Factors: A Preface
  • Burgeoning Global Population Offers Significant Growth Opportunities
    • Table 1: Top 25 Countries Worldwide in Terms of Population (2010 & 2013) (includes corresponding Graph/Chart)
  • Aging Global Population: Need for New Effective Drugs
    • Table 2: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
    • Table 3: Over-65 Years Population as a % of Total Population (2010 & 2020P) (includes corresponding Graph/Chart)
    • Table 4: Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)
  • Increasing Healthcare Spending in Emerging Markets: Opportunities in Store
    • Table 5: Healthcare Spending as % of GDP in Select Countries (2011) (includes corresponding Graph/Chart)
  • Global Spending on Medicines: A Review
    • Table 6: Global Medicine Spending (2013): Percentage Share Breakdown by Region/Country (includes corresponding Graph/Chart)
  • Biologics: Rapidly Gaining Ground
    • Table 7: Global Market for Biologics (2013E) - Percentage Share Breakdown of Sales by Therapy Area (includes corresponding Graph/Chart)
  • Erythropoietin (EPO) Market: An Insight
  • Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy
    • CKD Prevalence
    • Table 8: Number of ESRD Patients in the World (2010-2015) (includes corresponding Graph/Chart)
    • Table 9: Worldwide Dialysis Prevalence Rates (Patients per Million Population) for 2010-2015 (includes corresponding Graph/Chart)
    • Cancer Prevalence
    • Table 10: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported (in Thousands) for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 11: New Cancer Cases in the World by Affected Site (2012) (in Thousands) (includes corresponding Graph/Chart)
      • Cancer Prone Sites based on Age
    • Competition in EPO Market
      • Leading EPO Drugs Worldwide
      • Comparison of Erythropoietin-Based Drugs in America and European Union
    • Safety & Efficacy Issues Concerning ESAs
    • Serum Half-Life: A Key Attribute Differentiating ESAs
    • EPO's Illegal Use in Endurance Sports: A Cause of Concern
  • Interferons Market: Rising Demand for Specialized Therapies to Drive Growth
  • Patent Expiries of Major Interferon Drugs
  • Biosimilar Beta Interferon Market: EMA Guidelines to Hamper Investments?
  • Colony Stimulating Factors (CSFs) Market in Myeloma Patients
  • Neurotrophic Therapeutics: Recent Advancements & Challenges
  • Clinical Trial Status of Neurotrophin Therapy for Major Neurodegenerative Diseases (2012)
  • Interleukin-17 Market for Psoriasis Treatment: Positive Opportunities
  • Anti-IL-6 Pathways for RA Treatment: Favorable Prospects
  • Blood Growth Factors: Improving Circulation & Mobility in Peripheral Artery Disease Patients
  • Wound Management Market and Cellular Growth Factors
    • Table 12: Global Wound Growth Factors Market (2013): Percentage Share Breakdown of Sales by Region (includes corresponding Graph/Chart)
  • Multiple Sclerosis Drugs Market: Competition Set to Intensify
  • Interferon-based Drugs for HCV Treatment: An Insight
  • Patent Expiries Fuel Competition and Sales
  • Patent Expiries of Biopharmaceuticals in Europe and United States
  • Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors
  • Cytokines: Vital Growth Propellers for the Future of New Drugs
  • Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application
  • Mimetic Growth Factors - Promising Potential
  • New Technologies - Challenge to Growth Factors Market
  • Influence of Neurotrophic Factors on Brain Cell Development
  • Side Effects - Still a Concern
  • Combination of Interferons and Ribavirin Develops More Anemia Cases
  • Development of Cost Effective Methods - Need of the Hour
  • hMSC-based Therapies to Drive Need for Growth Factors

2. GROWTH FACTORS - AN OVERVIEW

  • Blood Growth Factors
  • Erythropoietins
    • Types of Erythropoietins
      • Epoetin
      • Darbepoetin
      • Aranesp(r)
      • Aranesp Vs. Other EPOs
    • Recombinant Human EPO (rHuEPO)
  • Colony Stimulating Factors
    • Granulocyte-Colony Stimulating Factor
    • Granulocyte Macrophage-Colony Stimulating Factor
    • Other Colony Stimulating Factors
      • Macrophage Colony Stimulating Factor (M-CSF)
      • Key Functions of M-CSF
    • Side-Effects of Colony-Stimulating Factors
  • Interferons
    • Types of Interferons
    • Interferon-gamma
    • 1a and 1b: Two Key Biochemical Forms of Interferon-β
    • PEG-Intron
      • Types of Interferons
  • Interleukins
    • Types of Interleukins
  • Tissue Growth Factors
  • Wound Healing Growth Factors
  • Neurotrophic Growth Factors
    • Nerve Growth Factor
  • Vascular Endothelial Growth Factor (VEGF)
  • Fibroblast Growth Factor (FGF)
  • Insulin-Like Growth Factor-I (IGF-I)
  • Insulin-Like Growth Factor-II (IGF-II)
    • Tissue Growth Factors: Classification Based on Key Source and Principal Activity
  • Platelet - Derived Growth Factors in Wound Healing
    • Thrombopoietin (TPO)
  • Growth Factors: Their Mode of Action in Tissue Repair
  • Angiogenesis: Their Role in Wound Healing
  • Angiogenesis As an Alternative for Cardiac Stents
  • Applications of Growth Factors
  • Growth Factors: Site/Course of Action and Applications

3. RESEARCH STUDIES & CLINICAL TRIALS

  • Aberrant Regulation of PDGFs & PDGFR in Solid Tumors
  • Stem Cell Combination Therapy Shows Improvement in Outcomes of Brain Injury
  • Cytokine IL-22 Promotes Pathogen Colonization
  • Amgen Releases Results of Phase III PAVES Study
  • Amgen Releases Phase 3 Aranesp(r) (darbepoetin alfa) RED-HF(r) Trial Results
  • FibroGen Releases Data of Phase 2 Hemoglobin Correction Study
  • Study Shows Therapeutic Potential of Neurotrophins
  • Study Shows Link between Improved Kidney Transplant Outcomes and Anemia Correction with EPO
  • Study Examines Intranasal Delivery of GDF5 to Brain
  • Bolder Publishes Research Supporting IL-11 Efficacy in Preventing Kidney Damage in Mice
  • Study Shows Varying Repair Rates for Growth Factor-based Treatment of Osseous Defects

4. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Sandoz Bags Japanese Approval for Biosimilar Filgrastim
  • Teva Markets Lipegfilgrastim in the UK
  • Nippon Kayaku Launches TevaGrastim in Japan
  • Teva Launches Lipegfilgrastim in Germany
  • SITC Guidelines for Melanoma Treatment Include Proleukin(r) by Prometheus Laboratories
  • Teva Receives EC Approval to Market Lonquex
  • Genexine's G-CSF Approved for Clinical Phase I by Korean Ministry
  • Nippon Receives Approval for G-CSF
  • SYGNIS Discontinues AX 200 Development
  • First G-CSF Biosimilar Approved in Japan
  • Dong-A to Launch Phase III Operations of Filgrastim
  • Dong-A Launches Phase III Operations of DA 3031
  • Teva's XM02 Filgrastim Approved by FDA to Treat Neutropenia
  • FibroGen's FG-3019 Granted Orphan Drug Designation by FDA
  • Mylan and Biocon Conducting Preclinical Evaluation of PEGfilgrastim
  • Aequus BioPharma in Preclinical Evaluation of AQB 101
  • Generon Begins Phase II Trials of F627
  • BioMimetic Therapeutics Receives Approval to Market GEM 21S in EU

5. RECENT INDUSTRY ACTIVITY

  • Five Prime Therapeutics Signs Collaboration Agreement with Bristol-Myers Squibb
  • Amgen to Halt EPO Manufacturing Operations at Colorado Plant
  • Regeneron and Bayer Collaborate to Develop Novel AMD Treatment
  • Amgen Acquires Franchise Rights on Filgrastim from Roche
  • Maxygen Shareholders Announce Dissolution Approval
  • Sangamo BioSciences Acquires Ceregene and its Alzhemier's Drug
  • Astrazeneca and Fibrogen Enter into Strategic Collaboration
  • Wright Medical Group and BioMimetic Therapeutics to Combine Businesses
  • Spectrum Pharmaceuticals In-Licenses G-CSF from Hanmi Pharmaceuticals
  • Pfizer Acquires Excaliard Pharmaceuticals
  • Transgene Biotek to Sell Erythropoietin Product to Tss Export GmbH
  • Shire Acquires Advanced BioHealing
  • Histogenics Takes Over ProChon Biotech
  • Terumo Americas Holding Buys Harvest Technologies Corporation

6. FOCUS ON SELECT PLAYERS

  • Alseres Pharmaceuticals, Inc. (USA)
  • Amgen, Inc. (USA)
  • Bayer HealthCare Pharmaceuticals, Inc. (USA)
  • Biogen Idec Inc (USA)
  • BioMimetic Therapeutics, Inc. (USA)
  • Biopharm GmbH (Germany)
  • Bolder Biotechnology, Inc. (USA)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Chugai Pharmaceutical Co. Ltd. (Japan)
  • Genentech, Inc. (USA)
  • FibroGen, Inc. (USA)
  • Johnson & Johnson (USA)
  • Janssen Biotech, Inc. (USA)
  • Lonza Group (Switzerland)
  • Merck Serono International S.A. (Switzerland)
  • NsGene A/S (Denmark)
  • PeproTech, Inc. (USA)
  • Reliance GeneMedix Plc (UK)
  • Sangamo BioSciences, Inc. (US)
  • Sanofi (France)
  • Shantha Biotechnics (India)
  • Scil Proteins GmbH (Germany)
  • Wockhardt Ltd. (India)

7. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 18: World 15-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 22: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 23: World Historic Review for Erythropoietins by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 24: World 15-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 25: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 26: World Historic Review for Colony Stimulating Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 27: World 15-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 28: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 29: World Historic Review for Interferons as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 30: World 15-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 31: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 32: World Historic Review for Interleukins as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 33: World 15-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 34: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 35: World Historic Review for Tissue Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 36: World 15-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Erythropoietin (EPO) Market: Amgen Continues to Dominate
      • Leading EPO Drugs in the US
    • Interferon Market: An Insight
      • HCV Therapy Market
    • Colony Stimulating Factors (CSF) Market: An Overview
      • Emerging Competitors in the G-CSF Market
    • Table 37: US Short Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP Nivestim, Neupogen, Sandoz EP2006, and TEVA Granix (includes corresponding Graph/Chart)
    • Table 38: US Long Acting Granulocyte Colony Stimulating Factors (G-CSFs) Market (2014 & 2020): Percentage Share Breakdown of Volume Sales for HSP peg-Filgrastim, Neulasta, Sandoz LA-EP2006, and TEVA Balugrastim (includes corresponding Graph/Chart)
      • US G-CSF New Entrants - Marketing Approval Status (2013)
    • US Fuels the Long-term Biosimilars Market
    • Table 39: Pharmaceutical Industry in the US (2013): Percentage Share Breakdown of Value Sales for Generic and Non-Generic Segments (includes corresponding Graph/Chart)
    • Table 40: US Pharmaceuticals Market (2013): Percentage Share Breakdown of Value Sales by Specialty and Non-Specialty Segments (includes corresponding Graph/Chart)
    • CDER: A Regulatory Review Authority for Growth Factors
    • Product Launches/Approvals/Innovations
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 41: US Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 42: US Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 43: US 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 44: Canadian Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 45: Canadian Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 46: Canadian 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Erythropoietin Market
      • Leading EPO Drugs in Japan
    • HCV Infection: Combination Therapy Dominates
    • Product Launches
    • Chugai Pharmaceutical Co. Ltd. - A Key Player
  • B. Market Analytics
    • Table 47: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 48: Japanese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 49: Japanese 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Erythropoietin Market
    • Leading EPO Drugs in Europe
    • Biosimilars Market
    • Table 50: Biosimilar Penetration in Select EU Countries (2013)
      • Biosimilars Currently Licensed in Europe
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 51: European Recent Past, Current & Future Analysis for Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 52: European Historic Review for Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 53: European 15-Year Perspective for Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 54: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 55: European Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 56: European 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • Market Analysis
    • Table 57: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 58: Asia-Pacific Historic Review for Growth Factors by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 59: Asia-Pacific 15-Year Perspective for Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for China and Rest of Asia-Pacific Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
    • Table 60: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 61: Asia-Pacific Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 62: Asia-Pacific 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Outlook
    • Erythropoietin Market
    • Table 63: Leading Players in the Chinese EPO Market (2013): Percentage Share Breakdown of Value Sales for 3SBio, Beijing Sihuan, Harbin Pharma, Nanjin Huaxin Pharma, and Others (includes corresponding Graph/Chart)
    • Injectable Interferons: The Only Treatment for HCV Patients
    • Hepatitis B Market: Smaller Role of Interferons
    • G-CSF Market: Competitive Landscape
    • Table 64: G-CSF Market in China (2013): Percentage Share Breakdown of Revenues by Agent - Filgrastim, Lenograstim, Molgramostim, Nartograstim, and Others (includes corresponding Graph/Chart)
    • Table 65: Leading Manufacturers in the Chinese G-CSF Market (2013): Percentage Share Breakdown of Revenues for Hangzhou Jiuyuan, Jiangsu Wuzhong Pharma, Qilu Pharma, Roche, Xiamen Amoytop Bio, Xiehe Fajio Qilin, and Others (includes corresponding Graph/Chart)
    • Biologics Market: An Overview
    • Table 66: Chinese Biologics Market (2013): Percentage Share Breakdown of Value Sales by Segment - EPO, G-CSF, Insulin, Interferon, Interleukin, mAb, Nerve Growth Factors, and Others (includes corresponding Graph/Chart)
    • Key Statistical Findings
      • Interleukins Market
    • Table 67: Interleukins Market in China (2013): Percentage Share Breakdown of Value Sales by Type - Interleukin-11 and Interleukin-2 (includes corresponding Graph/Chart)
    • Table 68: Leading Players in the Chinese Interleukins Market (2013): Percentage Share Breakdown of Value Sales for E China Pharm, Four Rings, QG Pharm, Qilu Pharm, SL Pharm, and Others (includes corresponding Graph/Chart)
      • Interferons Market
    • Table 69: Interferon Market in China (2013): Percentage Share Breakdown of Value Sales by Type of Interferon (includes corresponding Graph/Chart)
    • Table 70: Leading Players in the Chinese Interferons Market (2013): Percentage Share Breakdown of Value Sales for Hualida Bio, Huaxin Bio, Merck, Roche, Sinovac, Tri-Prime Gene, and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 71: Chinese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 72: Chinese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 73: Chinese 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

5b. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • India
      • Biopharmaceutical Drugs Market: Promising Opportunities
      • Erythropoietins
      • G-CSF Market
      • Interferons
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 75: Rest of Asia-Pacific Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 76: Rest of Asia-Pacific 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Brazil
      • HCV Therapy Market: Interferons Widely in Use
  • B. Market Analytics
    • Table 77: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes corresponding Graph/Chart)
    • Table 78: Rest of World Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 79: Rest of World 15-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins) and Tissue Growth Factors Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)
Show More
Pricing